Sun Pharma Buys Additional Stake In Taro, Will Tender Offer Follow?
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Alkaloida Chemical, an indirect subsidiary of Mumbai-based Sun Pharmaceutical, has bought a 9.4 percent stake in Taro Pharmaceutical from Brandes Investment Partners, taking Sun's holdings of the Israeli generic drug maker to 34.4 percent as it attempts to complete an acquisition that has stalled over the offer price
You may also be interested in...
India’s Sun Pharma To Pursue Taro Merger As Q4 Profits Surge On U.S. Protonix Sales
NEW DELHI - India's Sun Pharmaceutical said it is "on strong ground" to complete a merger with Taro Pharmaceutical at $10.25 a share, despite a rebuff by the Israel-based firm, as it reported higher than forecast earnings for the fourth quarter ended March 31 on strong sales of generic Protonix (pantoprazole) in the U.S
India’s Sun Pharma To Pursue Taro Merger As Q4 Profits Surge On U.S. Protonix Sales
NEW DELHI - India's Sun Pharmaceutical said it is "on strong ground" to complete a merger with Taro Pharmaceutical at $10.25 a share, despite a rebuff by the Israel-based firm, as it reported higher than forecast earnings for the fourth quarter ended March 31 on strong sales of generic Protonix (pantoprazole) in the U.S
Sun Pharmaceutical To Start Generic Protonix Sales in U.S.
NEW DELHI - India's Sun Pharmaceutical said it would immediately begin sales of a generic version of Wyeth's heartburn drug Protonix (pantoprazole) in the U.S., a move expected to be matched by Israel's Teva Laboratories for a market estimated at $2.3 billion